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possible reference to previous protocols, the extensive use of keywords to classify and recall patients according to their pathologies, the development of messages recommending maximal dose or minimal dosing interval, and increasing the safety of the analysis. We consider the program a valuable tool for adjusting aminoglycoside dosage in individuals. rialinfections, particularly those acquired in the hospital. The synergistic effects of using these drugs with beta-lactams and the relatively low and reversible bacterial resistance to aminoglycosides contributed to the success of the treatment.
The therapeutic activity seems to be directly dose-dependent and related tothe ratio of peak serum concentration to minimal inhibitory concentration (1).
However, aminoglycosides are associated with severe adverse effects. Primarily, nephrotoxicity and irreversible ototoxicity are described as accompanying high serum concentrations (2, 3). The toxicity seems to be associated with the area under the concentration-time curve (4) . Laboratory measurements are required to ensure adequate drug concentrations in body fluids and to adjust potentially toxic accumulations. Suggested conventional peak concentrations desired at the end of a 60-mm infusion for gentamicin, tobramycin, and netilmicin are 6 to 8 mg/L; "trough" concentrations before the next infusion should be between 0.5and 2 mgfL (4). For amikacin, the corresponding peak and trough values are 20 to 25 mg/L and between 2 and 10 mg/L, respectively (4) Numerous TDM program users share our need for a simple and convenient program to complete these sophisticated pharmacokinetic calculations.
To fill this gap, we developed the PHARMONITOR pro- 
MaterIals and Methods
Because the program is to be used inroutine TDM, we' gave priority to optimal data handling. PHARMONTrOR patients with different pathologies, of various ages and both sexes, with all patients being in steady-state regarding renal function (variations of serum creatinine >20% were excluded) and the aminoglycoside regimen (measurements after at least three infusions). Indeed, according to pharmacokinetic principles, a linear regression generally describes the relationship at steadystate between the elimination rate constant (ke) and the creatinine clearance. However, after stratifying our data, we observed an optimal linear regression correlating the drug half-life with the logarithm of the creatinine clearance, as presented in Table 2 for different aminoglycosides. Such a relationship, therefore, yields recommended intervals corresponding to the creatinine clearance ranges and tothe drug involved.
The maximal recommended dose (which can be modified by the user) is obtained from the medical literature, taking into account the patient's body weight and the frequency of drug administration (e.g., 20 mg/kg of usually of great help to determine the best dosage regimen. Recalculation of the data can be performed easily. Furthermore, retrospective population studies are possible by using diagnosis keywords characterizing each patient (patient populations could be assembled for statistical purposes: e.g., renal insufficient, premature). Users are free tocreate or modify their own database or keywords dictionary, concerning (e.g.) diagnoses, peak or trough target values, protocol comments, and the language of the printed reports.They can also add any other drug, as long as the target peak and trough concentrations are known.
In addition to the pharmacokinetic calculations described above, special messages prompt minimal recommended dosing interval and maximal dose, based respectively on the creatinine concentration in serum and from a population study and that from the individual kinetic calculation-should reinforce the choiceof the dosageregimen. On the other hand, a great disparity between both values should warn the user of a possible mistake in the sampling or in the evaluation of the creatinine clearance.
Results and Discussion
The reliability of the pharmacokinetic model used in the PHARMONITOR program has been assessedby comparing the peak and trough concentrations predicted by the program (equations 7 and 8) , before any dosage modification, with the corresponding serum concentrations observeda few days after the proposed modification. This study has been performed in a routine TDM environment, according tothe following criteria:
#{149} Measurements
were performed in steady-state (after at least the third infusion), with complete patients' data (creatinine, weight, timing, etc.).
#{149} Patients with unstable renal function (serum creatmine variations >20%) were rejected from the study. #{149} Patients maintained under the same dosage regimen, or patients whose calculated proposed treatment was not followed by the physician, were also rejected.
#{149} Patients younger than one year were excluded from this study.
#{149} Analyses of patients' samples always included two to four serum samples (drawn just before the infusion, and at least 1 h after the end of the infusion)and resulted in plausible kinetics; data presenting a great disparity between recommendation messages and individual kinetic calculations were excluded. #{149} Predicted and observed trough and peak drug concentrations were evaluated just before and just after infusion (t0). Peaks were extrapolated back tothe end of the infusion by using the slope calculated from the post-infusion concentrations.
The results presented in Table 3 demonstrate the usefulness of such calculations in predicting the optimal dosage regimen, and appear satisfactory in a TDM context. The slightly but statistically significant (P <0.05) higher values measured could be explained by a progressive accumulation of the drug in the deep compartment after several days of treatment Indeed, the use of one-compartment equations tends to underestimate aminoglycoside concentrations, particularly trough concentrations.
Because the correlation does not always accurately reflect the presence of a bias in the predicted values, the performance of this forecasting method has been further evaluated by calculating the bias and precision according to Sheiner and Beal (9) . For a population of 144 serum concentrations ranging from 0 to35 mgIL, including different aminoglycosides, the mean squared prediction error,a measure of precision, is here 6.55 (95% confidence interval, 3.33 to 9.76). The mean prediction error, a convenient measure of bias, is -0.81 (95% confidence interval, -1.28 to -0.33).
The To avoid any interference with the distribution phase (which could result in nonlinear kinetics), we strongly suggest collecting blood specimens at least 1 and 2 h after the end of the infusion for aminoglycosides and vancomycin, respectively. The successof such monitoring involves of course the compliance of the medical staff and nursing staff, who are asked to fill out a request form with the minimal biometric characteristics of the patient (weight, height, and age); the main biological has been routinely used since August 1989 to monitor >7000 patients' analyses, with a daily average of 25 patients.
In conclusion, once the limitations inherent in the pharmacokinetic model are well understood, this computer program is a useful tool for individual adjustment of aminoglycosides in a clinical environment, but obviously should not substitute for the clinician's judgment in the final decision, especially for critically ill and unstable patients. This program is designed to optimize the well-known method of pharmacokinetic forecasting of Sawchuk and Zaske (7) , by adapting this to the computer and by enhancing its safety by including recommendation messages based on population statistics. Both the kinetic model selected and the data-CLIN.CHEM.37/8, 1419-1423 (1991) handling contribute to the speed and reliability of the analysis.
We expect that the PHARMONITOR program could be used as the basic framework for other drug monitoring developments.
